Compass Therapeutics (CMPX) Change in Accured Expenses (2018 - 2026)

Compass Therapeutics has reported Change in Accured Expenses for 9 years, with the latest figure at -$3.4 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 148.84% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.2 million (down 145.74% YoY) and the FY2025 annual result came in at $5.1 million, up 35.06% from the prior year.
• Change in Accured Expenses retreated to -$3.4 million in Q1 2026 per CMPX's latest filing, from $2.7 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $6.9 million in Q1 2025 and troughed at -$5.4 million in Q2 2022.
• A 5-year average of -$45588.2 and a median of -$1.1 million in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses slumped 12354.55% in 2022, then soared 1090.99% in 2025.
• Over 5 years, Change in Accured Expenses stood at $5.9 million in 2022, then slumped by 152.62% to -$3.1 million in 2023, then soared by 207.7% to $3.4 million in 2024, then slipped by 19.93% to $2.7 million in 2025, then plunged by 225.34% to -$3.4 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$3.4 million, $2.7 million, and -$2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.